Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-offs [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward due to "recent launch dynamics" and high patient drop-off rates [5]. - Following the announcement, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charg ...

近日，重庆证监局发布了《关于对熊某采取出具警示函措施的决定》。 处罚书称，经查，熊某在证券经营机构工作期间，作为证券从业人员，存在未经投资者的委托， 擅自为投资 者卖出股票以及伪造投资者股票交易对账单 的问题。上述行为违反了《证券经纪业务管理办法》相关规定。 根据上述规定，重庆证监局对熊某采取出具警示函的行政监管措施，并记入证券期货市场诚信档案。 "你应切实强化证券法律法规知识学习，严格遵守法律法规，杜绝此类问题再次发生。"重庆证监局表示。 除此之外，券商中国记者还注意到，近期有多位证券从业人员被罚。 7月4日， 宁波证监局 发布了《关于对徐某采取出具警示函措施的决定》。经查，徐某在某券商宁波中山东路 证券营业部从业期间，在销售私募证券投资基金过程中存在误导性陈述并承诺投资收益的行为，违反了《证券 公司和证券投资基金管理公司合规管理办法》相关规定。 宁波证监局决定对徐某采取出具警示函的行政监管措施，并计入证券期货市场诚信档案。 7月1日， 厦门证监局 发布了《关于对张某采取出具警示函措施的决定》。经查，张某作为某券商厦门分公司 投资顾问，在公司未与客户签订证券投资顾问协议情况下通过个人微信向客户发送个股预测或 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by July 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements while concealing material adverse facts about the company's capital allocation priorities [4]. - Specifically, the lawsuit highlights that the defendants concealed the importance of Organon's debt reduction strategy following its acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. - The lawsuit claims that investors suffered damages once the true details about the company's financial priorities were revealed [4].

● 本报记者 赵中昊 中国证券报记者从业内获悉，为进一步完善证券行业执业声誉信息管理机制，中国证券业协会近期对 《证券行业执业声誉信息管理办法》进行了修订，目前正在征求行业意见。这是该办法运行三年后的首 次调整。 纳入违法失信信息范畴 《管理办法》的另一部分修订内容同样引发了业内高度关注。记者了解到，为了贯彻证监会"坚持受贿 行贿一起查"的部署，修订稿将"以贿赂等不正当手段干扰中国证监会及其派出机构监管执法工作，被予 以行政处罚、纪律处分，或者因情节较轻，未受到处罚处理，但被纪律检查或行政监察机构认定的信 息"纳入违法失信信息范畴。 业内人士认为，将行贿干扰监管纳入执业声誉管理后，涉事机构及个人将面临全行业联合惩戒。此次修 订体现出监管部门拟通过声誉资本定价机制让"围猎者"付出市场信用代价，是监管部门净化市场生态、 维护执法权威的又一项重要举措。内控薄弱的机构易因员工个人行为引发机构声誉风险，需加大合规投 入。 "这次修订给合规经营的同行打了一针'强心剂'。"一位资深券商合规人士对记者坦言。他所说的，正是 修订稿中明确写入的新内容：发行人因欺诈发行、虚假陈述给投资者造成损失，相关证券公司主动与受 到损失的投资 ...

天赐材料（002709） 广州天赐高新材料股份有限公司 第一条 为保障国家经济安全，保护社会公共利益，规范广州天赐高新材料股份有 限公司（以下简称"公司"）境外发行证券与上市相关的国家秘密和档案管理工作， 根据《中华人民共和国证券法》《中华人民共和国保守国家秘密法》（以下简称"《保 密法》"）、《中华人民共和国档案法》（以下简称"《档案法》"）、《中华人民 共和国国家安全法》《关于加强境内企业境外发行证券和上市相关保密和档案管理工 作的规定》 （中国证券监督管理委员会、财政部、国家保密局、国家档案局公告202344 号）《境内企业境外发行证券和上市管理试行办法》（中国证券监督管理委员会公告 202343号）《香港联合交易所有限公司证券上市规则》（以下简称"《香港上市规 则》"）等法律、法规、规范性文件的有关规定、公司股票上市地证券监管规则和《广 州天赐高新材料股份有限公司章程》（以下简称"《公司章程》"）规定，结合公司 情况，制定本制度。 第二条 本制度所称"境外发行证券与上市"是指公司在中华人民共和国大陆地 区以外的国家和地区发行证券并上市。本制度适用于公司境外发行证券与上市的全过 程，包括申请阶段、审核阶 ...

消费金融公司消费信贷资产证券化产品（ABS）密集发行。7月7日，北京商报记者注意到，海尔消费金 融有限公司（以下简称"海尔消金"）日前发行2025年第二期够花ABS，规模15亿元，其中优先A档票面 利率为1.8%，创行业年度新低。 这已是海尔消金年内第三次公开募资动作。2025年内的一次金融债、两次ABS发行，展示强劲融资实力 的背后，在海尔消金看来，得益于公司稳健可持续发展能力。海尔消金方面向北京商报记者表示，随着 政策对消费金融公司拓宽融资渠道持续"加码"，未来将根据公司经营目标需要，推动资产证券化产品及 金融债的常态化发行。 年内二次发行ABS，利率进一步下行 根据《够花2025年第二期个人消费贷款资产支持证券发行结果公告》，海尔消金第二期ABS于7月3日成 功发行，共计15亿元。其中，优先A级10.68亿元，占比71.2%，票面利率1.8%；优先B级1.24亿元，票 面利率1.95%；次级3.08亿元。 值得一提的是，今年3月，海尔消金发行了2025年第一期够花ABS，规模同样为15亿元，其中A档票面 利率为2.03%。截至目前，海尔消金累计在公开市场发行7单ABS产品，规模超百亿元。 ABS的发行， ...

7 July 2025 LEI: 2138003QW2ZAYZODBU23 LSE Code: 3USS WISDOMTREE MULTI ASSET ISSUER PUBLIC LIMITED COMPANY(a public company incorporated with limited liability in Ireland)WISDOMTREE S&P 500 3X DAILY SHORT SECURITIESISIN: IE00B8K7KM88 PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIESMEETING OF THE ETP SECURITYHOLDERS THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about what action you should take, you are recommended to consult your independent fi ...

记者了解到，此次修订的核心变化之一，直接回应了市场诉求和监管政策导向。此次修订明确写入一项 条款：发行人因欺诈发行、虚假陈述给投资者造成损失，相关券商主动与受到损失的投资者达成协议予 以先行赔付，积极减轻或消除投资者特别是中小投资者违法损害的，由其向协会申请，对相关行政处罚 信息不予记入执业声誉信息库。这为券商主动承担责任、化解风险提供了明确的"豁免通道"。 业内人士认为，中证协此举一方面进一步压实了中介责任，将赔付主动性纳入声誉评价，倒逼券商在项 目尽调、持续督导中更审慎履职，从源头降低欺诈风险；另一方面优化了投资者救济效率，缩短诉讼周 期，避免中小投资者因维权成本高而放弃索赔，从而提升市场信心。 与此同时，为了坚决贯彻证监会"坚持受贿行贿一起查"的部署，此次修订将"以贿赂等不正当手段干扰 中国证监会及其派出机构监管执法工作，被予以行政处罚、纪律处分，或者因情节较轻，未受到处罚处 理，但被纪律检查或行政监察机构认定的信息"纳入违法失信信息范畴。这意味着，无论是已被处以行 政处罚、纪律处分，还是情节虽轻未被上述方式处理但已被纪检监察机构认定的此类行为，都将清晰地 标记在券商及其从业人员的执业声誉记录上，其红线 ...